[Skip to Navigation]
June 1996

Juvenile Xanthogranuloma, Neurofibromatosis, and Juvenile Chronic Myelogenous Leukemia

Author Affiliations

Department of Dermatology Soroka Medical Center Beer-Sheva 84101, Israel

Arch Dermatol. 1996;132(6):712-713. doi:10.1001/archderm.1996.03890300142025

I read with great interest the editorial comments by Riccardi1 on the possible research implications of the article recently published by my colleagues and myself.2 However, I was confused by the notion of "the lack of an excess of inherited cases among patients with the triad of NF-1, JXG, and JCML." Our study showed a significant excess of familial neurofibromatosis type 1 (NF-1) among patients with the triad compared with patients with NF-1 and juvenile xanthogranuloma (JXG) but without juvenile chronic myelogenous leukemia (JCML) (85% vs 47%, P<.003). As I read further about "the canceling out of this excess [male preponderance] when the triad is present," the source of this and the previous misinterpretation has become obvious. The error was found in the labeling of two columns in Table 3 in the published article (Table, corrected); the column labeled JXG+NF+JCML and the corresponding footnote should now be

Add or change institution